(NASDAQ: CSTL) Castle Biosciences's forecast annual revenue growth rate of -0.3% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.31%.
Castle Biosciences's revenue in 2025 is $343,530,000.On average, 10 Wall Street analysts forecast CSTL's revenue for 2025 to be $9,455,666,083, with the lowest CSTL revenue forecast at $9,039,143,919, and the highest CSTL revenue forecast at $9,773,822,466. On average, 10 Wall Street analysts forecast CSTL's revenue for 2026 to be $9,336,284,468, with the lowest CSTL revenue forecast at $8,578,546,880, and the highest CSTL revenue forecast at $10,012,877,583.
In 2027, CSTL is forecast to generate $10,179,252,940 in revenue, with the lowest revenue forecast at $9,416,845,167 and the highest revenue forecast at $10,798,344,397.